Risk Factors for Adverse Events in Household Contacts Prescribed Preventive Treatment for Drug-resistant Tuberculosis Exposure
- 8 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (10), 1709-1715
- https://doi.org/10.1093/cid/ciaa327
Abstract
Background Completion of tuberculosis (TB) preventive treatment is important to optimize efficacy; treatment-related adverse events (AEs) sometimes result in discontinuation. This study describes the occurrence of AEs and their risk factors during a 6-month, 2-drug, fluoroquinolone-based preventive treatment for household contacts of patients with drug-resistant TB in Karachi, Pakistan. Methods The primary outcome was development of any clinical AE during preventive treatment. Adverse events were categorized using the AE grading tables of the National Institutes of Health. Time-to-event analysis with Kaplan-Meier curves and Cox proportional hazards models accounting for recurrence were used to analyze associated risk factors. Results Of the 172 household contacts on preventive treatment, 36 (21%) developed 64 AEs during 813 months of treatment. The incidence of AEs over 6 months of treatment was 7.9 per 100 person-months; 16 per 100 person-months with a fluoroquinolone and ethionamide, and 4.4 per 100 person-months with a fluoroquinolone and ethambutol. There were 53 (83%) grade 1 and 11 grade 2 AEs, with no grade 3 or 4 AEs. In multivariable analysis, the risk of AEs was higher in contacts prescribed ethionamide as compared to ethambutol adjusting for age, sex, and body mass index (adjusted hazard ratio, 2.1 [95% confidence interval {CI}, 1.2–3.6]). Overall, there was no notable difference in treatment completion among the contacts who experienced an AE and those who did not (crude odds ratio, 1.1 [95% CI, .52–2.5]). Conclusions A fluoroquinolone-based preventive treatment regimen for drug-resistant TB exposure is well tolerated. Regimens with ethionamide are more likely to result in AEs.Funding Information
- Global Health Delivery (K24AI114444)
- Emory University (P30AI050409)
- National Institutes of Health
This publication has 26 references indexed in Scilit:
- Moxifloxacin Prophylaxis against MDR TB, New York, New York, USAEmerging Infectious Diseases, 2015
- Management of Latent Tuberculosis Infection in Child Contacts of Multidrug-Resistant TuberculosisThe Pediatric Infectious Disease Journal, 2014
- Yield of Contact Investigations in Households of Patients With Drug-Resistant Tuberculosis: Systematic Review and Meta-AnalysisClinical Infectious Diseases, 2013
- Preventive Therapy for Child Contacts of Multidrug-Resistant Tuberculosis: A Prospective Cohort StudyClinical Infectious Diseases, 2013
- Management of Pediatric Contacts of Multidrug Resistant Tuberculosis in the United KingdomThe Pediatric Infectious Disease Journal, 2013
- Management of multidrug-resistant tuberculosis in children: a survival guide for paediatriciansPaediatric Respiratory Reviews, 2011
- Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohortThorax, 2009
- Management of Pediatric Multidrug-Resistant Tuberculosis and Latent Tuberculosis Infections in New York City From 1995 to 2003The Pediatric Infectious Disease Journal, 2008
- TuberculosisThe Lancet, 2003
- On the regression analysis of multivariate failure time dataBiometrika, 1981